Anne Davidson

List of Publications by Year
in descending order

123 papers	7,435 citations	70961 41 h-index	56606 83 g-index
138 all docs	138 docs citations	138 times ranked	7751 citing authors

#	Article	IF	Citations
1	Autoimmune Diseases. New England Journal of Medicine, 2001, 345, 340-350.	13.9	965
2	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	7.0	501
3	Induction of B7-1 in podocytes is associated with nephrotic syndrome. Journal of Clinical Investigation, 2004, 113, 1390-1397.	3.9	495
4	Taming lupusâ€"a new understanding of pathogenesis is leading to clinical advances. Nature Medicine, 2012, 18, 871-882.	15.2	390
5	What is damaging the kidney in lupus nephritis?. Nature Reviews Rheumatology, 2016, 12, 143-153.	3.5	220
6	Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis. Journal of Immunology, 2008, 180, 1938-1947.	0.4	214
7	Effect of longâ€term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, doubleâ€blind, placeboâ€controlled, doseâ€ranging study. Arthritis and Rheumatism, 2010, 62, 201-210.	6.7	198
8	Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis. Journal of Immunology, 2012, 189, 988-1001.	0.4	196
9	Similarities and differences between selective and nonselective BAFF blockade in murine SLE. Journal of Clinical Investigation, 2006, 116, 724-734.	3.9	196
10	Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. Cell, 2016, 166, 991-1003.	13.5	154
11	The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 1554-1562.	6.7	153
12	CTLA4Ig inhibits T cellâ€"dependent B-cell maturation in murine systemic lupus erythematosus. Journal of Clinical Investigation, 2000, 106, 91-101.	3.9	147
13	Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition. Journal of Immunology, 2003, 171, 489-497.	0.4	144
14	BAFF and selection of autoreactive B cells. Trends in Immunology, 2011, 32, 388-394.	2.9	141
15	Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3012-3017.	3.3	133
16	A Unique Hybrid Renal Mononuclear Phagocyte Activation Phenotype in Murine Systemic Lupus Erythematosus Nephritis. Journal of Immunology, 2011, 186, 4994-5003.	0.4	132
17	Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis and Rheumatism, 2012, 64, 2975-2985.	6.7	129
18	Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3524-3534.	0.4	128

#	Article	IF	Citations
19	BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. European Journal of Immunology, 2004, 34, 2750-2759.	1.6	119
20	Interferonâ€Î± accelerates murine systemic lupus erythematosus in a T cellâ€“dependent manner. Arthritis and Rheumatism, 2011, 63, 219-229.	6.7	117
21	Cross-reactivity of human lupus anti-DNA antibodies with ?-actinin and nephritogenic potential. Arthritis and Rheumatism, 2005, 52, 522-530.	6.7	105
22	Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis and Rheumatism, 2008, 58, 2824-2834.	6.7	101
23	Targeting BAFF in autoimmunity. Current Opinion in Immunology, 2010, 22, 732-739.	2.4	99
24	Mechanism of Action of Combined Short-Term CTLA4Ig and Anti-CD40 Ligand in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2002, 168, 2046-2053.	0.4	96
25	Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology, 1998, 27, 1368-1376.	3.6	93
26	Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis and Rheumatism, 2010, 62, 1457-1468.	6.7	92
27	Lupus nephritis: lessons from murine models. Nature Reviews Rheumatology, 2010, 6, 13-20.	3.5	82
28	Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 495-506.	6.7	81
29	Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nature Reviews Rheumatology, 2020, 16, 255-267.	3.5	74
30	Expansion and Hyperactivity of CD1d-Restricted NKT Cells during the Progression of Systemic Lupus Erythematosus in (New Zealand Black Ã— New Zealand White)F1 Mice. Journal of Immunology, 2005, 175, 763-770.	0.4	62
31	Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis, 2007, 28, 2614-2623.	1.3	59
32	BAFF inhibition: A new class of drugs for the treatment of autoimmunity. Experimental Cell Research, 2011, 317, 1270-1277.	1.2	58
33	Structure and Function of Renal Macrophages and Dendritic Cells From Lupusâ€Prone Mice. Arthritis and Rheumatology, 2014, 66, 1596-1607.	2.9	58
34	Integrated urine proteomics and renal single-cell genomics identify an IFN-Î³ response gradient in lupus nephritis. JCI Insight, 2020, 5, .	2.3	57
35	BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?. Immunological Reviews, 2008, 223, 156-174.	2.8	55
36	Identification of Stageâ€Specific Genes Associated With Lupus Nephritis and Response to Remission Induction in (NZB Ã— NZW)F1 and NZM2410 Mice. Arthritis and Rheumatology, 2014, 66, 2246-2258.	2.9	50

#	Article	IF	Citations
37	Renal Macrophages and Dendritic Cells in SLE Nephritis. Current Rheumatology Reports, 2017, 19, 81.	2.1	48
38	CTLA4Ig Prevents Initiation but not Evolution of Anti-phospholipid Syndrome in NZW/BXSB Mice. Autoimmunity, 2004, 37, 445-451.	1.2	47
39	Interferonâ€Î± treatment of female (NZW Ã— BXSB)F₁ mice mimics some but not all features associated with the Yaa mutation. Arthritis and Rheumatism, 2009, 60, 1096-1101.	6.7	46
40	Lupus nephritis: challenges and progress. Current Opinion in Rheumatology, 2019, 31, 682-688.	2.0	46
41	IFN-Î± Confers Resistance of Systemic Lupus Erythematosus Nephritis to Therapy in NZB/W F1 Mice. Journal of Immunology, 2011, 187, 1506-1513.	0.4	44
42	Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight, 2018, 3, .	2.3	44
43	IFNÎ± Inducible Models of Murine SLE. Frontiers in Immunology, 2013, 4, 306.	2.2	43
44	Plasma cells in systemic lupus erythematosus: The long and short of it all. European Journal of Immunology, 2011, 41, 588-591.	1.6	41
45	Comparative Transcriptional Profiling of 3 Murine Models of SLE Nephritis Reveals Both Unique and Shared Regulatory Networks. PLoS ONE, 2013, 8, e77489.	1.1	41
46	BAFF inhibition in SLEâ€"Is tolerance restored?. Immunological Reviews, 2019, 292, 102-119.	2.8	38
47	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	2.9	38
48	Inhibition of Helicobacter hepaticus-Induced Colitis by IL-10 Requires the p50/p105 Subunit of NF-ÎºB. Journal of Immunology, 2006, 177, 7332-7339.	0.4	37
49	HYDRALAZINE-INDUCED LUPUS: NO ASSOCIATION WITH HLA-DR4. Lancet, The, 1984, 323, 462.	6.3	36
50	Defects in Germinal Center Selection in SLE. Frontiers in Immunology, 2015, 6, 425.	2.2	36
51	Coâ€Stimulatory Blockade in the Treatment of Murine Systemic Lupus Erythematosus (SLE). Annals of the New York Academy of Sciences, 2003, 987, 188-198.	1.8	35
52	The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Research, 2004, 6, 197.	2.0	35
53	Antiâ€"tumor necrosis factor Î± treatment of interferonâ€Î±â€"induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis and Rheumatism, 2012, 64, 3399-3408.	6.7	34
54	Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy. FASEB Journal, 1992, 6, 2836-2842.	0.2	32

#	Article	IF	Citations
55	The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. Current Rheumatology Reports, 2012, 14, 295-302.	2.1	31
56	Targeting of the immune system in systemic lupus erythematosus. Expert Reviews in Molecular Medicine, 2008, 10, e2.	1.6	30
57	Pathogenesis and treatment of systemic lupus erythematosus nephritis. Current Opinion in Internal Medicine, 2006, 5, 631-638.	1.5	28
58	BAFF/APRIL Inhibition Decreases Selection of Naive but Not Antigen-Induced Autoreactive B Cells in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2011, 187, 6571-6580.	0.4	27
59	B-cell activating factor targeted therapy and lupus. Arthritis Research and Therapy, 2012, 14, S2.	1.6	27
60	Interferon alpha on NZM2328.Lc1R27: Enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure. Clinical Immunology, 2014, 154, 66-71.	1.4	27
61	Bim suppresses the development of SLE by limiting myeloid inflammatory responses. Journal of Experimental Medicine, 2017, 214, 3753-3773.	4.2	27
62	Enhanced Selection of High Affinity DNA-Reactive B Cells Following Cyclophosphamide Treatment in Mice. PLoS ONE, 2010, 5, e8418.	1.1	26
63	TheYaaLocus and IFN-Î± Fine-Tune Germinal Center B Cell Selection in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2012, 189, 4305-4312.	0.4	26
64	THE EFFECT OF CD28/B7 BLOCKADE ON ALLOREACTIVE T AND B CELLS AFTER LIVER CELL TRANSPLANTATION 1. Transplantation, 2001, 71, 801-811.	0.5	21
65	The Effect of BAFF Inhibition on Autoreactive B-Cell Selection in Murine Systemic Lupus Erythematosus. Molecular Medicine, 2016, 22, 173-182.	1.9	21
66	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
67	An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM) Tj ETQq1 1 0.784314 rgBT /Overlock	6.7	16
68	Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2012, 2012, 1-2.	3.3	16
69	TLR7 Influences Germinal Center Selection in Murine SLE. PLoS ONE, 2015, 10, e0119925.	1.1	16
70	Molecular studies of lupus nephritis kidneys. Immunologic Research, 2015, 63, 187-196.	1.3	15
71	Efficacy of the Combination of Metformin and CTLA4Ig in the (NZB Ã— NZW)F1 Mouse Model of Lupus Nephritis. ImmunoHorizons, 2020, 4, 319-331.	0.8	14
72	Fellow use of medical jargon correlates inversely with patient and observer perceptions of professionalism: results of a rheumatology OSCE (ROSCE) using challenging patient scenarios. Clinical Rheumatology, 2016, 35, 2093-2099.	1.0	13

#	Article	IF	Citations
73	A systems approach to renal inflammation in SLE. Clinical Immunology, 2017, 185, 109-118.	1.4	13
74	Editorial: Autoimmunity to Vimentin and Lupus Nephritis. Arthritis and Rheumatology, 2014, 66, 3251-3254.	2.9	12
75	Tinea versicolor associated with etanercept therapy. Journal of the American Academy of Dermatology, 2008, 58, S99-S100.	0.6	11
76	General Features of Autoimmune Disease. , 2014, , 19-37.		11
77	Renal Mononuclear Phagocytes in Lupus Nephritis. ACR Open Rheumatology, 2021, 3, 442-450.	0.9	10
78	From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine. Journal of Data Mining in Genomics & Proteomics, 2012, 03, .	0.5	10
79	A Rheumatoid Factor Specific Mimotope Identified by a Peptide Display Library. Autoimmunity, 1999, 30, 131-142.	1.2	9
80	Activated basophils give lupus a booster shot. Nature Medicine, 2010, 16, 635-636.	15.2	8
81	General Features of Autoimmune Disease. , 2020, , 17-44.		8
82	Autoimmunity Stimulated by Adoptively Transferred Dendritic Cells Is Initiated by Both Î±Î² and Î³Î´ T Cells but Does Not Require MyD88 Signaling. Journal of Immunology, 2007, 179, 5819-5828.	0.4	7
83	The Multiple Chemokine-Binding Bovine Herpesvirus 1 Glycoprotein G (BHV1gG) Inhibits Polymorphonuclear Cell but Not Monocyte Migration into Inflammatory Sites. Molecular Medicine, 2013, 19, 276-285.	1.9	7
84	Analysis of Renal Mononuclear Phagocytes in Murine Models of SLE. Methods in Molecular Biology, 2012, 900, 207-232.	0.4	7
85	Bone crisis of Gaucher's disease due to bone ischemia: A case report. Arthritis and Rheumatism, 1985, 28, 218-221.	6.7	6
86	Expression of Rheumatoid Factor Idiotypes 17.109, 6b6.6 and 4c9 in the Sera of Pima Indians. Autoimmunity, 1994, 18, 251-258.	1.2	6
87	Emerging areas for therapeutic discovery in SLE. Current Opinion in Immunology, 2018, 55, 1-8.	2.4	6
88	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	0.9	6
89	Use of anti-idiotypic antibodies to explore genetic mechanisms of production of anti-DNA antibodies. Cellular Immunology, 1986, 99, 44-52.	1.4	5
90	General Features of Autoimmune Disease. , 2006, , 25-36.		5

#	Article	IF	Citations
91	Sustaining the Rheumatology Research Enterprise. Arthritis Care and Research, 2015, 67, 1187-1190.	1.5	5
92	Promise and complexity of lupus mouse models. Nature Immunology, 2021, 22, 683-686.	7.0	5
93	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	1.1	5
94	Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. Blood, 2020, 136, 33-34.	0.6	5
95	Speculation on the Role of Somatic Mutation in the Generation of Anti-DNA Antibodies. Annals of the New York Academy of Sciences, 1986, 475, 174-179.	1.8	4
96	Molecular Characterization of Monoclonal IgM Derived from Human B Cell Lines Expressing the 4C9 Rheumatoid Factor Associated Idiotype. Autoimmunity, 1995, 20, 171-183.	1.2	4
97	Pathogenetic Mechanisms in Lupus Nephritis. , 2013, , 237-255.		4
98	Age-associated B cells acquire a new wrinkle. Nature Immunology, 2018, 19, 317-318.	7.0	4
99	Reversible dysregulation of renal circadian rhythm in lupus nephritis. Molecular Medicine, 2021, 27, 99.	1.9	4
100	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology, 2020, 59, 1505-1513.	0.9	3
101	ORIGINS OF ANTI-DNA ANTIBODIES. , 1986, , 277-287.		3
102	Rubicon promotes rather than restricts murine lupus and is not required for LC3-associated phagocytosis. JCI Insight, 2022, 7, .	2.3	3
103	B cells twist and shout. Immunology and Cell Biology, 2009, 87, 512-513.	1.0	2
104	Inhibitory short synthetic oligodeoxynucleotides and lupus. Arthritis Research and Therapy, 2009, 11, 116.	1.6	2
105	204â€...The immune cell landscape in kidneys of lupus nephritis patients. , 2019, , .		2
106	Process and Analysis of Kidney Infiltrates by Flow Cytometry from Murine Lupus Nephritis. Bio-protocol, 2012, 2, .	0.2	2
107	Context-dependent induction of autoimmunity by TNF signaling deficiency. JCI Insight, 2022, 7, .	2.3	2
108	IgG binding enhances DNAase I sensitivity of N-acetoxy-N-2-acetylaminofluorene-modified Î¦X-174 RF DNA. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1985, 825, 80-88.	2.4	1

#	Article	IF	Citations
109	New immune modulatory drugs for systemic lupus erythematosusâ€"what can we expect?. Nature Clinical Practice Rheumatology, 2006, 2, 638-639.	3.2	1
110	Future advances in pharmacogenomics: BAFF, APRIL and plasma cells. International Journal of Clinical Rheumatology, 2010, 5, 281-285.	0.3	1
111	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€"The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.4	1
112	Somatic Mutation. , 1998, , 2192-2193.		0
113	Activated Interstitial Macrophages are Important Mediators of SLE Nephritis. Clinical Immunology, 2007, 123, S88.	1.4	0
114	OR.14. IFNÎ± Accelerates SLE in a T Cell Dependent and BAFF Independent Manner. Clinical Immunology, 2008, 127, S8-S9.	1.4	0
115	Identification of stage-specific genes associated with lupus nephritis and response to remission induction in NZB/W and NZM2410 mice. Arthritis Research and Therapy, 2014, 16, A21.	1.6	0
116	TD-02â€...Kidney tissue damage in mice with single and combined abnormalities in complement, interferon and apoptotic cell clearance. , 2018, , .		0
117	AB0167â€...SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY. , 2019, , .		0
118	205â€...Single cell RNA expression in lupus nephritis comparing african-american and caucasian patients identifies differential expression of type I interferon pathway. , 2019, , .		0
119	Contribution of BAFF and DNAâ€containing Immune Complexes to the Generation of DNAâ€reactive B cells. FASEB Journal, 2008, 22, 668.17.	0.2	0
120	Isolation of Dendritic Cells and Macrophages from the Murine Kidneys of Lupus by Cell Sorter. Bio-protocol, 2012, 2, .	0.2	0
121	BAFF and APRIL and Their Receptors. , 2014, , 181-187.		0
122	509â€...The localization of novel macrophage subsets in class III and IV lupus nephritis kidney sections. , 2021, , .		0
123	Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche. Blood, 2021, 138, 1989-1989.	0.6	0